653 related articles for article (PubMed ID: 19581800)
1. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
Nielsen VG; Kirklin JK; George JF
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
[TBL] [Abstract][Full Text] [Related]
2. Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasma.
Nielsen VG; Kirklin JK; George JF
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):377-80. PubMed ID: 19417630
[TBL] [Abstract][Full Text] [Related]
3. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
4. Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in hemophilia A, hemophilia B and factor VII-deficient plasmas.
Nielsen VG; Kirklin JK; George JF
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):41-5. PubMed ID: 19923981
[TBL] [Abstract][Full Text] [Related]
5. Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity.
Malayaman SN; Cohen JB; Machovec KA; Bernhardt BE; Arkebauer MR; Nielsen VG
Blood Coagul Fibrinolysis; 2011 Jun; 22(4):345-8. PubMed ID: 21330914
[TBL] [Abstract][Full Text] [Related]
6. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
Nielsen VG; Steenwyk BL; Gurley WQ
J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
[TBL] [Abstract][Full Text] [Related]
7. Carbon monoxide releasing molecule-2 attenuates the anticoagulant and amplifies the hypofibrinolytic effects of hypothermia in human plasma in vitro.
Nielsen VG; George SJ
Blood Coagul Fibrinolysis; 2011 Jan; 22(1):67-72. PubMed ID: 21157299
[TBL] [Abstract][Full Text] [Related]
8. Carbon monoxide releasing molecule-2 enhances coagulation and diminishes fibrinolytic vulnerability in subjects exposed to warfarin.
Nielsen VG; Khan ES; Kirklin JK; George JF
Thromb Res; 2010 Jul; 126(1):68-73. PubMed ID: 20406708
[TBL] [Abstract][Full Text] [Related]
9. Carbon monoxide releasing molecule-2 decreases thick diameter fibrin fibre formation in normal and Factor XIII deficient plasmas.
Nielsen VG; Kirklin JK; George JF; Messinger JD
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):101-5. PubMed ID: 19844175
[TBL] [Abstract][Full Text] [Related]
10. Carbon monoxide releasing molecule-2 enhances coagulation and attenuates fibrinolysis by two mechanisms: insights gained with colloid dilution.
Cohen JB; Persaud JM; Malayaman SN; Nielsen VG
Blood Coagul Fibrinolysis; 2011 Jan; 22(1):60-6. PubMed ID: 21157300
[TBL] [Abstract][Full Text] [Related]
11. Quantification of the effects of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin on fibrinolysis in normal human plasma.
Nielsen VG; Ellis TC
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):29-33. PubMed ID: 17179823
[TBL] [Abstract][Full Text] [Related]
12. Iron and carbon monoxide attenuate Crotalus atrox venom-enhanced tissue-type plasminogen activator-initiated fibrinolysis.
Nielsen VG; Boyer LV; Matika RW; Amos Q; Redford DT
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):511-6. PubMed ID: 26575490
[TBL] [Abstract][Full Text] [Related]
13. Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma.
Nielsen VG
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):191-6. PubMed ID: 19657316
[TBL] [Abstract][Full Text] [Related]
14. Carbon monoxide releasing molecule-2 improves protamine-mediated hypocoagulation/hyperfibrinolysis in human plasma in vitro.
Nielsen VG; Malayaman SN; Cohen JB; Persaud JM
J Surg Res; 2012 Apr; 173(2):232-9. PubMed ID: 20950825
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plasmin interactions.
Nielsen VG
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):647-56. PubMed ID: 17890952
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
Kramkowski K; Leszczynska A; Mogielnicki A; Chlopicki S; Fedorowicz A; Grochal E; Mann B; Brzoska T; Urano T; Motterlini R; Buczko W
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
[TBL] [Abstract][Full Text] [Related]
18. Carbon monoxide-releasing molecule-2 enhances coagulation and diminishes fibrinolytic vulnerability in diluted plasma in vitro.
Nielsen VG; Green P; Green M; Martin-Ross A; Khan ES; Kirklin JK; George JF
J Trauma; 2011 Apr; 70(4):939-47. PubMed ID: 20693919
[TBL] [Abstract][Full Text] [Related]
19. Carbon monoxide and nitric oxide modulate α₂-antiplasmin and plasmin activity: role of heme.
Arkebauer MR; Kanaparthy SS; Malayaman SN; Vosseller K; Nielsen VG
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):712-9. PubMed ID: 22024794
[TBL] [Abstract][Full Text] [Related]
20. The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2.
Machovec KA; Ushakumari DS; Welsby IJ; Nielsen VG
Thromb Res; 2012 Jun; 129(6):793-6. PubMed ID: 21872302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
